Aayog Protect Aayog Advance
  • Share this portfolio
  • Previous Portfolio
  • Next Portfolio
  • Portfolio List
  • Close Video


January 5, 2016

Deflazacort 6 mg (Micronized) Tablet

Category: Corticosteroids with mainly glucocorticoid activities, which reduces inflammation and suppress allergic reactions and immune system activity

The drug is indicated in Wide range of conditions which need steroid treatment.
Chronic inflammatory skin conditions
Asthma, COPD
Allergic conditions
Duchenne muscular dystrophy
Idiopathic thrombocytopenic purpura
Juvenile chronic arthritis, Rheumatoid arthritis
Nephrotic syndrome
Systemic lupus erythematosus
Transplanted organ rejection, Solid organ

Dosage of administration:
In terms of equivalent potency, deflazacort 6 mg is equivalent to prednisone 5 mg.

The dose of deflazacort should be based on patient characteristics, diagnosis, severity of disease, clinical response and tolerability. The lowest possible dose that controls disease symptoms should be utilized to minimize the potential adverse effects of deflazacort.

General dosing guidelines are 6 to 18 milligrams/daily taken in the morning to mimic circadian rhythm of corticosteroid release from the body. For maintenance therapy, the dose may be doubled and taken every other morning. By dosing in accordance with circadian rhythms, potential adverse drug effects are minimized.

Adults- Acute disorders, up to 120mg daily may be needed. Maintenance doses are usually in the range of 3-18mg daily.

Children- doses usually lie in the range 0.25-1.5mg/kg/day

Hypersensitivity to deflazacort. Systemic fungal infections

Adverse effects:
Skin changes such as acne, hirsutism, petechiae, ecchymosis, have been reported as adverse effects associated with deflazacort therapy. Signs of Cushing’s syndrome due to deflazacort have included moon facies, flushing, truncal obesity are reported to be less severe when compared to prednisone. Dyspepsia and pancreatitis have been reported as adverse effects of deflazacort therapy.

Gastric ulcers have been reported as a side effect of deflazacort therapy, with severity such that it was necessary to discontinue drug therapy. Osteoporosis has been reported as an adverse effect of deflazacort therapy.

CNS adverse effects which may occur with deflazacort therapy include headache, dizziness, insomnia, agitation, euphoria, and psychological disorders such as hypomania and depression. Muscle weakness may occur with deflazacort therapy.

Cataracts and increased intraocular pressure have been reported as an adverse effect of deflazacort therapy. Amenorrhea may occur as an adverse effect of deflazacort therapy.

How does deflazocort differs from other steroids?
It is an oxaline derivative of prednisolone. Addition of oxaline group remarkably reduces lipid solubility, which is responsible for lesser incidences of adverse effects. In terms of equivalent potency, deflazacort 6 mg is equivalent to prednisone 5 mg..